Role of Pharmaceutical Companies in Dupixent Litigation: Failure to Warn and Liability

Role of Pharmaceutical Companies in Dupixent Litigation: Failure to Warn and Liability

Dupixent litigation has brought to light critical questions about how pharmaceutical companies like Sanofi and Regeneron manage drug safety and communicate risks to patients and healthcare providers. Dupixent, approved for eczema, asthma, and other inflammatory conditions, has been linked to severe side effects such as eye disorders, facial inflammation, and joint pain. Plaintiffs allege that Sanofi and Regeneron failed to provide adequate warnings about these risks, exposing patients to harm that could have been prevented.

The heart of the lawsuits centers on whether the manufacturers knew-or should have known-about Dupixent’s risks and failed to take reasonable steps to inform physicians and the public. These claims strike at the core of corporate responsibility in the pharmaceutical industry, where companies must balance profit motives with patient safety obligations. When warnings are incomplete or misleading, the consequences can lead to long-term injury, massive litigation, and erosion of public trust.

By examining the allegations and the legal framework surrounding failure to warn claims, it becomes clear how Dupixent litigation reflects broader accountability issues in drug manufacturing and marketing practices.

Failure to Warn: The Central Issue in Dupixent Lawsuits

At the center of the Dupixent lawsuits lies the claim of “failure to warn.” This legal theory asserts that Sanofi and Regeneron did not adequately warn consumers and physicians about the potential risks associated with Dupixent. Under U.S. product liability law, a manufacturer has a duty to disclose known or foreseeable risks of its product. Plaintiffs allege that the companies breached this duty by omitting critical safety information from labeling, advertising, and physician guidance materials.

Many patients taking Dupixent reported developing severe eye inflammation (such as conjunctivitis and keratitis), chronic facial redness, and systemic immune reactions that significantly impacted their quality of life. Attorneys argue that these side effects were known to the manufacturers based on clinical trial data and post-market reports but were not emphasized or clearly described in warnings provided to doctors and consumers.

Pharmaceutical failure-to-warn claims often focus on the adequacy and visibility of risk communication. Courts consider whether the warnings were timely, sufficiently detailed, and appropriately directed toward healthcare professionals. When evidence shows that adverse effects were downplayed or omitted, liability for negligence becomes a significant risk for the manufacturer.

In the Dupixent litigation, this issue goes beyond technical labeling-it raises ethical and regulatory questions about the integrity of drug safety disclosure and the mechanisms that are supposed to protect the public from preventable harm.

Sanofi and Regeneron’s Role in Risk Management and Post-Market Oversight

Sanofi and Regeneron jointly developed and market Dupixent, meaning both companies share legal and regulatory responsibility for post-market surveillance and reporting. The U.S. Food and Drug Administration (FDA) requires drug manufacturers to monitor adverse event data, update labels, and issue safety communications as new risks are identified. Plaintiffs allege that Sanofi and Regeneron failed to fulfill these obligations in a timely manner.

Post-market oversight is not simply a regulatory checkbox-it is a continuing duty to ensure patient safety. When thousands of reports of eye inflammation and facial swelling began to surface, critics argue the companies should have initiated label changes or issued public safety updates sooner. Instead, updates reportedly lagged, leaving doctors and patients unaware of the scope and seriousness of these complications.

This alleged delay in risk communication is central to claims of negligence and breach of duty. A manufacturer’s duty to warn extends throughout the product’s lifecycle, meaning they cannot rely on initial clinical trial data alone. As new patterns of harm emerge, companies are expected to act decisively to protect consumers. Plaintiffs contend that Sanofi and Regeneron failed to take those necessary steps, prioritizing sales growth over transparency.

These failures, if proven, could demonstrate a systemic breakdown in how pharmaceutical companies manage and communicate drug safety risks-an issue that could have far-reaching implications beyond Dupixent itself.

Corporate Accountability and Ethical Obligations in Drug Safety

At its core, Dupixent litigation challenges the ethical standards of corporate responsibility within the pharmaceutical industry. Drug manufacturers wield immense influence over medical practice, shaping treatment decisions through marketing, sponsored research, and physician education. When safety information is incomplete or selectively presented, it undermines both patient care and medical ethics.

Corporate accountability extends beyond compliance with FDA regulations. Companies have a moral duty to prioritize public health over profit. In the case of Dupixent, plaintiffs argue that Sanofi and Regeneron failed to meet this obligation by not being transparent about potential harms. The litigation claims that these corporations prioritized market share expansion-particularly in the lucrative dermatology and asthma markets-over full disclosure of safety concerns.

This pattern of alleged misconduct is not unique. Historically, pharmaceutical litigation has revealed similar themes: delayed warnings, manipulated trial data, and aggressive marketing tactics aimed at minimizing perceived risks. When these behaviors are repeated, they demonstrate a troubling industry culture that tolerates risk concealment as a cost of doing business.

For victims suffering long-term injuries from Dupixent, holding these companies accountable is not only about compensation-it is about demanding honesty, transparency, and systemic reform to prevent future harm.

Legal Theories of Liability in Dupixent Litigation

Several distinct legal theories underpin the Dupixent lawsuits, each focusing on a different aspect of corporate negligence and consumer protection. Plaintiffs typically assert claims under:

• Failure to Warn: Alleging inadequate communication of known side effects and failure to update labeling.
• Design Defect: Claiming Dupixent’s formulation or mechanism of action carries unreasonable risks not justified by its benefits.
• Negligence: Arguing that Sanofi and Regeneron breached their duty of care in testing, monitoring, and disclosing safety information.
• Breach of Implied Warranty: Contending that the drug was not as safe or effective as represented.
• Fraudulent Misrepresentation: Alleging that the companies intentionally concealed or mischaracterized risks to increase sales.

Each of these theories requires plaintiffs to establish that the companies knew or should have known about Dupixent’s dangers and failed to act responsibly. Internal communications, trial data, and post-market surveillance reports often become critical evidence in such cases. When companies are found to have ignored red flags, courts may impose punitive damages to deter future misconduct.

The complexity of pharmaceutical litigation underscores the need for meticulous investigation, expert testimony, and strong evidentiary support. Our firm assists clients in navigating these challenges, ensuring that every case is built on a foundation of medical and legal rigor.

How Regulatory Oversight Shapes Pharmaceutical Liability

The relationship between the FDA and drug manufacturers plays a key role in determining liability. While FDA approval provides a level of defense for companies, it does not absolve them from responsibility when new risks emerge post-approval. Courts have consistently held that FDA compliance does not shield a manufacturer from failure-to-warn claims if the company withheld or downplayed critical safety data.

Under the FDA’s “Changes Being Effected” (CBE) regulation, drug manufacturers can unilaterally update labels to strengthen warnings without prior FDA approval. Plaintiffs in the Dupixent litigation argue that Sanofi and Regeneron had the opportunity-and the obligation-to use this mechanism once significant eye-related adverse events became apparent.

Failure to exercise that authority can amount to negligence. The CBE rule exists precisely to ensure that safety warnings can be updated quickly when new evidence arises. If the companies chose not to act, it strengthens claims that they valued profits over protection. Regulators may now reevaluate how such oversight mechanisms are enforced, especially when multiple reports point to a pattern of delay in communicating risks to the public.

Ultimately, the Dupixent litigation illustrates how regulatory compliance is not the end of corporate responsibility-it is only the beginning. True accountability requires proactive risk management and transparent communication at every stage of a drug’s market life.

Lessons for the Pharmaceutical Industry

The Dupixent lawsuits send a powerful message to the entire pharmaceutical sector: risk management must be proactive, not reactive. Companies cannot rely on the FDA alone to identify and mitigate safety issues. A culture of transparency-where internal data and patient feedback are taken seriously-is essential to rebuilding public trust in prescription drug safety.

Pharmaceutical firms should implement robust internal audit systems to track adverse event data, review labeling accuracy, and assess marketing claims. Independent safety committees and external medical oversight can further ensure that decisions about risk disclosure are guided by science, not sales projections.

Sanofi and Regeneron’s handling of Dupixent’s post-market risks may serve as a cautionary case study for other drug manufacturers. When corporate leadership treats safety communication as a legal formality instead of a moral duty, litigation becomes inevitable.

These lawsuits could ultimately drive reforms in how companies approach safety transparency, potentially leading to stronger penalties for delayed warnings and stricter post-market monitoring requirements.

Taking Action: Protecting Your Rights in Dupixent Litigation

Individuals who have suffered serious side effects after taking Dupixent have legal rights. Compensation may be available for medical expenses, pain and suffering, lost wages, and other damages linked to Sanofi and Regeneron’s alleged failure to warn. Holding these corporations accountable can also help prevent future harm to others who rely on prescription medications.

If you or someone you know experienced severe adverse reactions from Dupixent, our lawyers at Alonso Krangle, LLP are ready to help evaluate your case and pursue justice. Our team understands the complexities of pharmaceutical litigation and fights to ensure that negligent companies are held responsible for the harm they cause.

To learn more about your options in the Dupixent litigation, contact Alonso Krangle, LLP today at [PHONE] or complete our confidential online form. Taking legal action can provide not only compensation but also the accountability needed to promote safety across the drug industry.